Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma
Sponsor: Seagen Inc.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Seagen Inc.
- HER2-positive Metastatic Breast Cancer · Phase PHASE2 · May 2025
- Appendiceal Adenocarcinoma · Phase PHASE1 · Mar 2024
- Carcinoma, Non-Small-Cell Lung · Phase PHASE1 · Dec 2023
- Bladder Cancer · Phase PHASE1 · Dec 2023
- Multiple Myeloma · Phase PHASE1 · Nov 2023
More terminations from Seagen Inc.
A PHASE2 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Seagen Inc. and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Oct 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seagen Inc.
For direct contact, visit the study record on ClinicalTrials.gov .